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A b s t r a c t
Coronary chronic total occlusions (CTO) are increasingly encountered during invasive and non-invasive coronary angiography and 
remain the most challenging lesions for percutaneous revascularization. During recent years success rates and safety outcomes of CTO 
percutaneous coronary intervention (PCI) have substantially improved, particularly due to the introduction of new techniques and dedicat-
ed equipment as well as specialized training programs of CTO operators. Significantly, the steady advances in CTO PCI techniques have co-
incided with the new data from randomized clinical trials supporting the role of percutaneous recanalization of CTO in relieving angina and 
improving the quality of life. The current expert consensus document outlines the rationale, clinical outcomes as well as technical, safety 
and reimbursement issues of CTO PCI. In addition, the requirements for achieving and maintaining competency in CTO PCI among inter-
ventional cardiologists are discussed. Finally, we present the modified hybrid algorithm (the so-called Polish hybrid algorithm) providing 
some unique refinements to the contemporary CTO PCI strategies. Continuous efforts (including active engagement with the payer) are 
urgently needed to increase guideline-recommended referrals to CTO PCI, and thus improve the quality of life of CTO patients in Poland.
Key words: coronary chronic total occlusion, percutaneous coronary intervention, hybrid algorithm.
S u m m a r y
Coronary chronic total occlusions (CTO) are increasingly encountered during invasive and non-invasive coronary angiogra-
phy and remain the most challenging lesions for percutaneous coronary intervention (PCI). During recent years success rates 
and safety outcomes of CTO PCI have substantially improved, and successful recanalization of CTO has been shown to relief 
angina and improve the quality of life based on randomized clinical trial data. Nevertheless, and contrary to the Western 
European countries, CTO PCI is significantly underused and accounts for < 3% of all PCI in Poland. The current expert con-
sensus summarizes the rationale, clinical outcomes as well as technical and safety issues of CTO PCI. Significantly, we have 
presented the modified hybrid algorithm (the “so called” Polish hybrid algorithm) providing some unique refinements to the 
contemporary CTO PCI strategies. Finally, the list of succinct and practical recommendations on CTO PCI has been provided. 
Continuous efforts are urgently needed to expand the knowledge on CTO PCI and close the gap between Poland and Western 
European countries.
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Introduction
During recent years success rates and safety of per-
cutaneous coronary intervention (PCI) in chronic total 
occlusion (CTO) have substantially improved, particularly 
due to the introduction of new techniques and dedicat-
ed equipment as well as specialized training programs of 
CTO operators. Development of new wires and microca-
theters, refinement of retrograde and hybrid techniques 
as well as periprocedural guidance using invasive and 
non-invasive imaging tools allowed to achieve success 
rates exceeding 90% in luminary centers with highly ex-
perienced CTO operators [1–3]. The current consensus 
document summarizes contemporary data on CTO PCI 
including up-to-date recommendations of the EuroCTO 
Club, Global Consensus and Polish experts opinions to 
help disseminate the latest knowledge and recommen-
dations among practicing physicians [4, 5].
Coronary CTO is still the last barrier to complete per-
cutaneous revascularization of patients with coronary 
artery disease. The presence of CTO, defined as an angio-
graphic finding of complete occlusion of a coronary ves-
sel of more than 3 months duration, is a common finding 
during routine coronary angiography, with a prevalence 
between 18% and 52% [6–11]. Despite high frequency of 
severe ischemia and angina resistant to medical therapy 
in most patients with CTO, the rate of attempted CTO 
PCI is low and averages 10%, with the Canadian multi-
center registry showing wide variability in attempt rates 
ranging between 1 and 16% across different centers [11]. 
Based on the unpublished data from the Polish nation-
wide registry (ORPKI) on 535,857 patients treated with 
PCI between 2014 and 2018, only 12,572 (2.3%) patients 
underwent CTO PCI. This implies that patients selected 
for CTO PCI are often chosen according to the operator’s 
subjective opinion rather than the actual clinical need. 
Still, it is not uncommon for certain centers that patients 
with clear indication for revascularization are denied CTO 
PCI because of the absence of skills, tools or concerns in 
terms of the potential complications as well as non-ade-
quate financial support of CTO procedures by the Nation-
al Health Fund in Poland. At the other extreme, patients 
with simple CTO lesions, but no clear clinical indication 
for revascularization, are referred for CTO PCI. The lack of 
appropriate knowledge about the potential clinical bene-
fits of CTO PCI, which is undeniably a more complex pro-
cedure with higher costs than the regular PCI of non-CTO 
lesions, has led to reluctance to refer these patients for 
percutaneous revascularization from the wider cardiolo-
gy community [12].
Indications
Currently there is a modest level of evidence for the 
most optimal treatment of CTO. Significantly, patients 
with CTO lesions appropriate for intervention are those 
who are symptomatic (including both angina and/or dys-
pnea) despite optimal medical therapy (OMT). Hence, the 
European Society of Cardiology (ESC) guidelines assign 
CTO PCI a  class IIa indication, whereby percutaneous 
revascularization of CTO should be considered in pa-
tients with angina resistant to medical therapy or with 
a large area of documented ischemia in the territory of 
the occluded vessel [13–19]. At the same time the au-
thors of the ESC guidelines affirm that “broadly speak-
ing, the treatment of CTO may be considered analogous 
to the treatment of non-CTO lesions” [13]. In addition, it 
is recommended that complex CTO procedures are only 
performed by adequately experienced interventionalists 
(class IIa, level of evidence C). However, there is ambigu-
ity in the definitions of appropriate indications as well as 
sufficient “operator expertise”. In our opinion, PCI should 
be equally indicated in a patient with CTO (currently class 
IIa) as compared to a patient with a non-occlusive critical 
coronary stenosis (currently class I), provided that both 
lesions induce the same level of ischemia and symptoms.
Two recently published randomized controlled clinical 
trials and several observational studies reported symp-
toms improvement after successful CTO PCI [14, 20]. The 
EUROCTO trial randomized 396 patients in a 2 : 1 fash-
ion to CTO PCI plus OMT or OMT alone. Significantly, all 
non-CTO lesions were treated before randomization to 
assign the intrinsic effect of revascularization to CTO. The 
success rate of CTO recanalization was 87%, and the trial 
showed superiority of PCI over OMT for angina frequency 
and quality of life at 12 months follow-up. In addition, 
physical limitation and functional angina class also im-
proved in the CTO PCI arm [14]. The IMPACTOR-CTO trial 
included 94 patients with isolated CTO of the RCA and 
showed a significant decrease of ischemia burden as well 
as improvement of functional status and quality of life in 
the CTO PCI group versus the OMT group [20]. 
In contrast, two randomized controlled clinical trials 
showed neutral effects of CTO PCI. The EXPLORE trial 
randomized 304 patients after PCI for ST-segment eleva-
tion myocardial infarction (STEMI) to subsequent PCI or 
OMT for concomitant CTO. The primary endpoints were 
defined as left ventricular ejection fraction and left ven-
tricular end-diastolic volume assessed by cardiac mag-
netic resonance at 4 months follow-up. Although the trial 
was negative, some methodological flaws (including slow 
recruitment and site volume with the mean of 2.4 pa- 
tients/year/center, relatively low CTO PCI success rate 
of 73%, high crossover rate of 23%, and finally the lack 
of inducible myocardial ischemia test before PCI) might 
have influenced the results [21]. In lieu of these findings, 
the authors found that there were more patients with 
freedom from angina after CTO PCI at 1-year follow-up 
[22]. Another negative trial was the DECISION CTO trial, 
in which 834 patients were allocated to either CTO PCI 
or no CTO PCI. After 4.0 years of follow-up, there was no 
significant difference between the CTO-PCI and the no 
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CTO-PCI strategies in the incidence of death, myocardial 
infarction, stroke, or any revascularization [23]. Never-
theless, the DECISION CTO trial was widely criticized due 
to its design (revascularization of non-CTO lesions was 
allowed in both groups and observed in more than 70% 
of patients, extremely low enrolment rate, 18% crossover 
rate, inclusion of all-cause death and stroke in the pri-
mary endpoint), and based on our opinion should not be 
taken into consideration when interpreting the potential 
benefits of CTO PCI [24]. 
In observational studies CTO PCI relieved regional 
ischemia and was associated with improved exercise 
capacity, increased anaerobic threshold, and fewer de-
pressive symptoms [25–29]. Subsequently, it was proven 
that viable myocardium supplied by a CTO is a persistent-
ly ischemic zone [30, 31]. Both regional and global left 
ventricular function improved after successful CTO PCI in 
patients with viability or baseline dysfunction [32]. This 
result was, however, not confirmed in two randomized 
controlled trials [21, 33]. Nevertheless, these random-
ized studies were performed in patients with preserved 
left ventricular function, did not examine the presence 
of viable and dysfunctional myocardium, nor did they 
assess exercise induced changes in left ventricular func-
tion. Also, patients with a  coronary CTO who received 
an implantable cardioverter defibrillator for primary or 
secondary prevention had a  higher risk for ventricular 
arrhythmias as well as higher frequency of recurrent 
ventricular tachycardia after ablation than patients with 
non-occlusive coronary stenoses [34–36]. However, there 
are no randomized studies assessing whether CTO PCI 
may reduce the risk for subsequent arrhythmias. Im-
portantly, in observational studies, patients presenting 
with acute MI (including both STEMI and non-STEMI) 
and a CTO in a non-culprit coronary artery had a high-
er risk of worse clinical outcomes as compared with pa-
tients without a  CTO [37–39]. Also, a  meta-analysis of 
6 studies including 1253 patients showed that CTO PCI 
of the non-infarct-related artery in patients presenting 
with STEMI was associated with a significant reduction 
in major adverse cardiac events (MACE), cardiovascular 
mortality, and heart failure readmission [40].
In a meta-analysis of 25 observational studies compar-
ing successful vs. failed CTO PCI, patients with a success-
ful procedure had lower mortality [30]. Moreover, obser-
vational studies demonstrated a lower incidence of MACE 
after successful CTO PCI as compared with OMT alone 
irrespective of the quality of the collateral circulation 
[9, 41, 42]. Although CTO PCI might improve hard clinical 
outcomes, particularly among patients with a large isch-
emic burden (e.g. ischemia of > 10% of the myocardium) 
in whom complete revascularization is achieved [43–47], 
this hypothesis still requires confirmation in a  well-de-
signed, prospective, randomized clinical trial. 
The belief that all CTO lesions are benign is likely 
unsubstantiated, and there are situations where inter-
vention is highly indicated. Hence, a patient with CTO re-
quires comprehensive assessment of symptoms (includ-
ing arrhythmia), left ventricular function, ischemia, and/
or viability prior to revascularization (Figure 1). In case of 
persisting angina and/or exertional dyspnea unrelated to 
other conditions (i.e. anemia or chronic obstructive pul-
monary disease) and preserved left ventricular function, 
a high burden of ischemia is almost always present, and 
the referral for CTO PCI should be considered after metic-
ulous assessment of the risk to benefit ratio.
Of note, the decision to embark on CTO PCI should be 
discussed within the broader group of physicians includ-
ing the physician in charge, non-invasive cardiologist and 
invasive cardiologist trained in CTO PCI. Equally import-
ant is a  thorough discussion between a  physician and 
a patient about the course and the length of the proce-
dure, its potential complications as well as the expected 
clinical benefit.
Figure 1. Indications for CTO PCI according to symptoms, ischemia, and viability
CTO – chronic total occlusion, PCI – percutaneous coronary intervention.
Medical history Exertional symptoms 
(Angina/Dyspnoe*/Fatigue/Ventricular arrhythmia) 
Viability Ischemic burden ≥ 10% 
Revascularization 
(PCI or CABG) 
Revascularization 
(PCI or CABG) 
Normokinesia  
or hipokinesia in  
CTO territory
Revascularization 
(PCI or CABG) 
Akinesia or dyskine-
sia in CTO territory 
Medical therapy 
Akinesia or dyskine-
sia in CTO territory 
Medical therapy 
Normokinesia  




imaging tests  
(MRI, SPECT, PET)
Yes No
Yes No Yes No
*After exclusion of anemia,  
COPD and asthma 
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Angiogram analysis
CTO PCI requires meticulous preparation. The first 
step includes careful and structured review of the an-
giogram, and also, if available, coronary computed to-
mography angiography (coronary CTA) [4]. It is generally 
discouraged to perform ad-hoc CTO PCI after diagnostic 
angiography so as to leave sufficient time for angiogram 
analysis, planning the procedure, and preparation of the 
availability of the catheterization laboratory as well as 
the whole team involved in the procedure. It is recom-
mended to routinely perform dual catheter injection un-
less retrograde filling of CTO is absent via the donor ar-
tery [4]. Such an approach allows for better visualization 
and appreciation of CTO anatomy and prevents repetitive 
antegrade injections with increased risk of dissections 
during guidewire manipulation. According to the EuroC-
TO Club database, on average 75% of all CTO PCI are 
performed with dual catheter injection [5]. The review of 
angiogram should focus on 4 crucial CTO characteristics: 
1) proximal cap morphology; 2) occlusion length, course 
and composition (visible calcium), 3) quality of distal ves-
sel and distal cap morphology, 4) characteristics of the 
collateral circulation. Below we present the main ratio-
nale for the assessment of each of the above-mentioned 
angiographic characteristics:
•	 Determination of the morphology of the proximal cap 
is crucial for selection of the most optimal approach – 
antegrade in case of a well-defined cap or retrograde 
in case of proximal cap ambiguity. Alternatively, ad-
ditional imaging tools – such as intravascular ultra-
sound (IVUS) or coronary CTA (in selected cases with 
CT co-registration availability) or less often selective 
contrast injection via the microcatheter – can be em-
ployed for clarifying proximal cap ambiguity.
•	 Lesion length can be accurately assessed by dual in-
jection or coronary CTA. Both coronary calcification 
and vessel tortuosity can be better determined by 
coronary CTA than invasive angiography.
•	 Distal vessel size as well as the presence of resid-
ual coronary artery disease and bifurcation at the 
distal cap should be routinely evaluated to gauge 
the chances of success in antegrade dissection and 
re-entry (ADR) technique.
•	 Evaluation of collaterals is essential for deciding on 
a retrograde approach and should be obtained with 
high-quality angiography (optimally during breath 
hold and without panning) in different projections. 
Collateral size, tortuosity, bifurcations, entry and exit 
angles, as well as the distance from the collateral exit 
to the distal cap must be assessed. Lack of tortuosity 
and the optimal size increase the chances of success-
ful guidewire crossing. Currently, the Werner classifi-
cation is used to assess the quality of collaterals (CC0 
– no continuous connection, CC1 – threadlike connec-
tion, CC2 – side branch-like connection) [48]. Selec-
tive contrast tip injection through a  microcatheter 
using a 2 to 3 ml syringe can allow proper visualiza-
tion of the collateral pathway. Septal collaterals are 
usually safe and relatively easy to cross using soft tip 
guidewires and can be dilated using small profile bal-
loons in case of difficulty in microcatheter passage. 
The epicardial pathway should be reserved for very 
experienced PCI operators in adequately equipped 
centers prepared to treat epicardial collateral perfora-
tion with coils or other techniques (selective fat em-
bolization, thrombin injection).
CTO scores
Currently, there is a large number of scores (includ-
ing angiographic, computed tomographic and clinical 
parameters) which were developed to estimate the dif-
ficulty level of CTO. The historically first and most used 
scoring system is the relatively simple J-CTO score, which 
was originally validated to estimate the likelihood of suc-
cessful and time-efficient (within 30 min) antegrade wire 
crossing. The J-CTO score is based on 5 variables: blunt 
proximal cap, bending > 45° within the CTO segment, oc-
clusion length ≥ 20 mm, visible calcification, and previ-
ously failed attempt [48, 49]. Each present parameter is 
assigned one point and all points are summed to calcu-
late the total J-CTO score and stratify lesion difficulty as: 
easy (J-CTO score of 0), intermediate (J-CTO score of 1), 
difficult (J-CTO score of 2), and very difficult (J-CTO score 
> 3 points). In addition, the J-CTO score has been val-
idated to predict 1-year target lesion revascularization 
after successful CTO PCI [50]. Other angiographic scores 
to predict technical success of CTO PCI include: PROG-
RESS-CTO score [51], RECHARGE registry score [52], 
CL-score [53], ORA score [54], Ellis score [55], W-CTO 
score [56] and CASTLE score [57]. Also, it is endorsed to 
assess the risk of periprocedural complications by using 
the PROGRES CTO Complications Score [58].
Besides angiographic scores, coronary CTA-based 
scoring systems, including the CT-RECTOR score (Com-
puted Tomography Registry of Chronic Total Occlusion 
Revascularization) [59] and the KKCT score (Korean 
Multicenter CTO CT registry score) [60], were developed. 
Noteworthy, both of these scores have superior diagnos-
tic accuracy as compared with the angiographic J-CTO 
score for prediction of time-efficient guidewire crossing 
and final procedural success. Although coronary CTA is 
still rarely applied for planning and periprocedural guid-
ance of CTO PCI, it surpasses invasive angiography for 
visualization of calcification, proximal cap ambiguity, 
tortuosity, and distal CTO segment [61]. Consequently, 
coronary CTA is particularly useful for guiding PCI in CTO 
lesions with poor visualization on invasive angiography 
such as long CTO, ostial occlusions, CTO in patients after 
coronary artery bypass grafting and previously failed CTO 
PCI. In addition, 3-dimensional CTA can be displayed and 
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automatically aligned with the fluoroscopic C-arm in the 
catheterization laboratory so as to aid in: 1) selection of 
the most optimal angiographic projection with the least 
vessel foreshortening; 2) clarification of proximal cap 
ambiguity; 3) navigation of guidewire crossing along the 
occlusion site; and 4) facilitating the most optimal re-en-
try site in dissection and re-entry techniques. Currently, 
the wider application of coronary CTA for guiding CTO PCI 
is limited to a  few luminary centers with availability of 
advanced angiography systems with in-built CT applica-
tions.
Access site
The choice of arterial access depends on the clinical 
situation and operator preference and can include var-
ious sites: bifemoral, biradial, radial and femoral, and 
least often two ipsilateral femoral sheaths. When choos-
ing the femoral approach, it is advocated to use long 
(35 to 45 cm) and armed 7 Fr or 8 Fr sheaths. Although 
some operators prefer the radial approach (common-
ly using slender 7 Fr sheaths or less often regular 6 Fr 
sheaths) over the femoral approach, the benefit of reduc-
ing access site complications should be balanced against 
lesser supportive power of the smaller guiding catheters 
[62]. Hence, the radial approach for the donor artery and 
the femoral approach for the CTO vessel are frequently 
regarded as the most optimal solution for maintaining 
optimal support and reduction of arterial access compli-
cations.
Guiding catheters
CTO PCI requires optimal guiding catheter support 
(both passive and active) with coaxial alignment, and an 
adequately large lumen to host additional devices [5]. It 
is advised to use guiding catheters with side holes to pre-
vent dissections unless ADR technique is contemplated 
as the most likely strategy. Most operators use 7 Fr guides 
or 8 Fr guides for the CTO vessel, and 7 Fr guides or 6 Fr 
guides for contralateral injection. For the left coronary 
artery extra backup guides (EBU) are preferred, although 
in some situations (such as CTO of the circumflex artery) 
the Amplatz guide can be advantageous. For the right 
coronary artery the Amplatz left guide is preferred as the 
most supportive guiding catheter, with other guides be-
ing used in specific anatomic situations (Judkins, Amplatz 
right, RBU, IMA, 3D RC, shepherd’s crook, hockey stick 
curves). The CTO PCI operators should be familiar with 
balloon anchoring and mother-in-child techniques.
Guidewires
During recent years substantial progress in guidewire 
technology has been achieved allowing for increased 
success rates of CTO recanalization despite growing le-
sion complexity [5]. Expertise in the composition and 
properties of the guidewires is mandatory for CTO PCI 
operators. Generally, guidewires can be divided into 
3 categories according to the stiffness of its tip: soft 
(≤ 1 gr), intermediate (2–6 gr) and stiff (> 9 gr). Soft ta-
pered polymeric composite core wires are intended for 
soft tissue tracking (passive wire control), intermediate 
tapered composite core guidewires are mostly applied for 
hard tissue tracking (active wire control), whereas stiff 
tapered wires are designed for calcified tissue penetra-
tion including highly resistant proximal cap crossing. In 
the current era, Fielder family wires (Asahi Intecc, Na-
goya, Japan) including Fielder XT, XT-R and XT-A are most-
ly used for soft tissue tracking. In contrast, for active 
wiring (called the “deflection and rotation” technique) 
the Gaia family (Asahi Intecc, Nagoya, Japan) is preferred. 
The most commonly used stiff wires with high tipload/
penetration force include Confianza Pro 12 (Asahi Intecc, 
Nagoya, Japan) and Hornet 14 (Boston Scientific, Marl-
borough, MA, USA). For the retrograde approach and col-
lateral crossing, the preferred guidewires include Sion, 
Sion Black, Suoh 3 and Fielder XT-R (all Asahi Intecc, Na-
goya, Japan). Subintimal tracking using the knuckle wire 
technique is usually performed with polymer jacketed 
guidewires such as Fielder XT or Fielder XT-A (both Asahi 
Intecc, Nagoya, Japan), Pilot 200 (Abbott Vascular, USA) 
or Fighter (Boston Scientific, Marlborough, MA, USA). Re-
cently, the dedicated polymer jacketed and hydrophilic 
coating knuckle wire Gladius Mongo (Asahi Intecc, Na-
goya, Japan) with increased lubrication and torque trans-
mission has been introduced. An overview of currently 
available guidewires is presented in Table I.
Microcatheters
Microcatheters allow for safe delivery, enhanced nav-
igation with adequate support and quick replacement of 
the guidewires and are essential for procedural success 
of CTO PCI [4, 5]. Specifically, the distance between the 
tip of the microcatheter and the CTO entry site can alter 
the penetration force, and thus the mechanical proper-
ties of the guidewire. Moreover, microcatheters allow not 
only for rapid exchange but also for multiple tip reshap-
ing of the guidewires. Ultimately, following successful 
guidewire CTO crossing, microcatheters are advanced to 
the distal CTO segment beyond the occlusion site, en-
abling lesion dilatation and modification. In retrograde 
technique, microcatheters dilate collaterals channels and 
protect them from wire-induced trauma. In specific an-
atomic situations (parallel wire technique, side branch 
at proximal cap, bifurcation, wiring of difficult collater-
als) dual lumen microcatheters can be successfully em-
ployed. Microcatheter selection depends on CTO angio-
graphic characteristics, operator’s preference, and local 
availability. In contrast, over-the-wire balloons (still uti-
lized by some operators due to financial constraints) are 
hampered by significant limitations (including difficulty 
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Table I. An overview of CTO guidewires
Company Guidewire Tip stiffness [g] Polymeric Hydrophilic tip
Abbott Vascular Whisper LS 0.8 Yes Yes
Whisper MS 1.0 Yes Yes
Whisper ES 1.2 Yes Yes
PILOT 50 1.5 Yes Yes
PILOT 150 2.7 Yes Yes
PILOT 200 4.1 Yes Yes
Cross-It  100 1.7 No No
Cross-It  200 3 No No
Cross-It  300 4 No No
Cross-It  400 6 No No
Progress 40 4.8 No No
Progress 80 9.7 No No
Progress 120 13.9 No No
Progress 140T 12.5 No No
Progress 200T 13.9 No No
Asahi Intecc SION 0.7 No Yes
SION blue 0.5 No No
SION blue ES 0.5 No No
SION black 0.8 Yes Yes
SUOH 0.3 0.3 Yes Yes
Fielder FC 0.8 Yes Yes
Fielder XT 0.8 Yes Yes
Fielder XT-A 1.0 Yes Yes
Fielder XT-R 0.6 Yes Yes
Gladius 3 Yes Yes
Gladius Mongo 3 Yes Yes
Gaia First 1.7 No Yes
Gaia Second 3.5 No Yes
Gaia Third 4.5 No Yes
Gaia Next 1 2 No Yes
Gaia Next 2 4 No Yes
Gaia Next 3 6 No Yes
MIRACLEbros 3, 6 and 12 No No
ULTIMATEbros 3 3 No No
Confianza 9 No No
Confianza Pro 9, 12 and 20 No No
Astato XS 20 and 40 20 and 40 No No
Astato 30 30 No No
RG3 3 No Yes
Boston Scientific Samurai 0.5 No Yes
Samurai RC 0.5 No Yes
Fighter 1.2 Yes Yes
Hornet 1 No Yes
Hornet 10 10 No Yes
Hornet 14 14 No Yes
Cordis/J&J Shinobi 7 Yes Yes
Shinobi Plus 6.8 Yes Yes
Medtronic Persuader 3 and 6 3 and 6 No Yes
Persuader 9 9 No Yes
Terumo Runthrough NS Floppy 1 No Yes
Runthrough NS Hypercoat 1 Yes Yes
Runthrough NS Intermediate 3.6 No Yes
Crosswire NT 7.7 No Yes
Crosswire Hard type 40 15.6 No Yes
Crosswire Hard type 80 26.7 No Yes
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in precise location of the tip, inefficient balloon advance-
ment, and tendency to kink), and should not be routinely 
used in CTO PCI. In Table II the key characteristics of mi-
crocatheters used for CTO PCI are presented.
CTO PCI techniques and hybrid algorithm
The main strategies in CTO PCI are classified as fol-
lows: 1) antegrade wire escalation, 2) ADR, 3) retrograde 
wire escalation, and 4) retrograde dissection and re-entry 
[4, 5].
Antegrade wire escalation is the most common initial 
CTO PCI strategy [2, 63–65]. It is based on different wires’ 
properties that are used according to CTO characteristics: 
(tapered stump or visible channels – polymer-jacketed 
low penetration force guidewires; blunt stump – interme-
diate and high penetration guidewires; highly resistant 
cap – high penetration guidewires). In each case escala-
tion and de-escalation strategies are recommended de-
pending on the particular situation. In case of subintimal 
tracking, parallel wire technique (optimally assisted by 
dual lumen microcatheter) can be implemented to avoid 
enlargement of the subintimal space [5]. Alternatively, 
ADR technique can be applied. 
ADR technique can be either used as a  first-choice 
CTO PCI strategy or in case of failed antegrade wiring or 
retrograde techniques [66]. The main concept of ADR is 
to enter the subintimal space, cross the occlusion site, 
and ultimately re-enter into the distal true lumen. The 
historically first ADR technique, called subintimal track-
ing and re-entry (STAR), is fully uncontrollable and can 
result in unnecessary stenting of long vessel segments 
with potentially higher risk for loss of the side branches 
and subsequent re-occlusion [67–69]. It was thus sub-
sequently replaced with the “investment procedure” re-
lying on subintimal plaque modification (using balloon 
predilatation) with delayed stenting for enhanced chanc-
es of antegrade wiring during repeat procedure [70, 71]. 
In contrast, the modern ADR relies on the application of 
dedicated re-entry systems such as the CrossBoss cath-
eter and the Stingray balloon (both Boston Scientific, 
Marlborough, MA, USA) to minimize vascular injury, limit 
the length of the dissection and stenting segment, and, 
to some extent, preserve the side branches, leading to 
favorable clinical outcomes [72–75]. In addition, many 
other dissection techniques were developed to achieve 
successful re-entry into the true distal lumen (miniSTAR 
[76], limited antegrade subintimal tracking [77]) or pen-
etrate the proximal cap (scratch and go, balloon assisted 
subintimal entry or Carlino [78]). Of particular interest, 
recently a  novel and relatively simple ADR technique, 
Table II. An overview of coronary microcatheters
Company Microcatheter Dual-lumen Length Distal shaft outer 
diameter
Asahi Intecc Caravel No 135 cm, 150 cm 1.9 Fr
Corsair Pro No 135 cm, 150 cm 2.6 Fr
Corsair Pro XS No 135 cm, 150 cm 2.1 Fr
Sasuke Yes 145 cm 2.5 × 3.3 Fr
Tornus No 135 cm 2.1 Fr and 2.6 Fr
Boston Scientific Mamba No 135 cm 2.4 Fr
Mamba Flex No 135 cm, 150 cm 2.1 Fr
IMDS NHancer Pro X (NX3 and NX6) No 135 cm, 155 cm 2.0 and 2.3 Fr
NHancer Rx Yes 135 cm 2.3 × 3.3 Fr
ReCross Yes (3 exit ports) 140 cm 2.3 × 3.3 Fr
Kaneka Crusade Yes 140 cm 2.9 Fr
Mizuki Standard and Mizuki FX No 135 cm, 150 cm 1.8 Fr and 1.7 Fr
Terumo Finecross No 130 cm, 150 cm 1.8 Fr
FineDuo Yes 140 cm 2.9 Fr
Teleflex SuperCross (45°, 90° or 120° tip angle) No 130 cm, 150 cm 2.1 Fr
Turnpike No 135 cm, 150 cm 2.6 Fr
Turnpike Spiral No 135 cm, 150 cm 3.1 Fr
Turnpike LP No 135 cm, 150 cm 2.2 Fr
Turnpike Gold No 135 cm 3.2 Fr
Twin-Pass and Twin-Pass Torque Yes 135 cm 2.7 × 3.4 Fr and  
3.5 × 3.5 Fr
Venture No 145 cm (rapid exchange)
140 cm (over-the-wire)
2.2 Fr
Asahi Intecc, Aichi, Japan; Boston Scientific Corp., Marlborough, MA, USA; IMDS, Roden, the Netherlands; Kaneka, Tokyo, Japan; Terumo Corp., Tokyo, Japan; 
Teleflex/Vascular Solutions, Minneapolis, MN, USA.
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called antegrade fenestration and re-entry, has been in-
troduced, wherein multiple fenestrations are created at 
the level of the distal cap followed by advancement of 
a polymer-jacketed guidewire from the subintimal space 
into the distal true lumen [79, 80].
In the retrograde approach, the CTO is approached 
from the donor artery after advancing the guidewire 
and microcatheter through collaterals [81]. In some cas-
es, it is feasible to cross the occlusion site into the true 
lumen (retrograde wire escalation technique), followed 
by guidewire externalization and subsequent conversion 
to the antegrade approach. In the majority of retrograde 
cases, however, the reverse controlled antegrade and ret-
rograde tracking (reverse CART) technique has to be ap-
plied, wherein the balloon is inflated over the antegrade 
wire followed by retrograde wiring into the space created 
by the antegrade balloon, and subsequently the proximal 
true lumen of the CTO [3].
The integration of the above-mentioned techniques 
resulted in the concept of the “hybrid algorithm”, propa-
gated by the North American operators [82]. Specifically, 
it is based on the premise that rapid switch of CTO PCI 
strategies in case of failure increases procedural efficien-
cy. Noteworthy, such an approach is particularly salient 
in lesions with a high J-CTO score, wherein the chances 
of antegrade wire escalation fall to 30–40% [83]. The hy-
brid algorithm relies on the assessment of 4 angiograph-
ic features of CTO (proximal cap ambiguity, quality of the 
distal vessel, presence of interventional collaterals and 
occlusion length) that determine the initial PCI strategy 
and potential alternative techniques in case of failure. It 
has been confirmed that the application of the hybrid al-
gorithm enhances procedural success rates (~90%) and 
safety [2]. After introduction of the hybrid algorithm, 
the Asia Pacific CTO Club algorithm was developed with 
some modifications (highlighted role of IVUS in proximal 
cap ambiguity, IVUS-guided wiring as a bailout strategy 
in the antegrade approach, use of parallel wire technique, 
use of CrossBoss catheter as a strategy of choice for in-
stent CTO, and lack of CTO length as a determinant for 
choosing the initial antegrade strategy) [84]. Significant-
ly, in 2019 the EuroCTO Club proposed a modified hybrid 
algorithm for CTO PCI, emphasizing the role of antegrade 
techniques to resolve proximal cap ambiguity (balloon 
assisted subintimal entry, scratch and go, IVUS-guided 
puncture) and giving equal relevance to ADR and parallel 
wire technique after failing antegrade wiring [5].
Cessation of CTO PCI
It is essential for minimizing complications and low-
ering the radiation dose to determine conditions for 
stopping CTO PCI in case of repeated failures. Hence, 
it is advocated to stop the procedure when there is no 
apparent progress of CTO PCI and: 1) procedural time is 
> 3 h, 2) contrast volume exceeds 4× the eGFR, or 3) the 
radiation dose is > 5 Gy [5]. In case of failure and planning 
a second attempt, CTO PCI should be re-attempted after 
6 to 8 weeks. Although re-attempted CTO is associated 
with higher angiographic complexity as well as longer 
procedural and fluoroscopy time, in experienced hands 
the success and complication rates were reported to be 
similar as compared with the first attempt CTO PCI [85].
Drug-eluting stents and intravascular  
ultrasound
Drug-eluting stents are recommended after successful 
recanalization of CTO so as to reduce the rates of MACE, 
restenosis and re-occlusion as compared to bare metal 
stents [5]. While optimal stent sizing and expansion are 
paramount for improved long-term outcomes (including 
MACE and definite/probable stent thrombosis), the use of 
IVUS is particularly advocated in CTO PCI [86–89]. In addi-
tion, IVUS plays a pivotal role in the antegrade and retro-
grade approach for: 1) identification of the proximal cap, 
2) antegrade reentry from the subintimal space, 3) retro-
grade guidewire crossing, 4) reverse CART technique [5]. In 
the EuroCTO Club database, the use of IVUS in CTO PCI in-
creased from 5% in 2011 to almost 17% in 2019 (including 
16% in antegrade and 23% in retrograde procedures) [90].
Pharmacology during and after procedure
For achieving optimal periprocedural anticoagulation 
an initial bolus (100 IU/kg) of intravenous unfractionated 
heparin (UFH) is routinely administered, and the activat-
ed clotting time (ACT) should be monitored every 30 min 
for the antegrade and every 20 min for the retrograde 
approach (optimally a dedicated nurse or a technician is 
assigned to monitor ACT). An additional bolus of UFH is 
administered to maintain ACT > 250–300 s during ante-
grade and > 350 s during retrograde procedure [5].
Dual antiplatelet therapy (DAPT) for at least 6 months 
following stenting is currently recommended in patients 
with stable ischemic heart disease (class I recommenda-
tion) [91]. Prolonged (up to 30 months) DAPT duration 
may be considered (class IIb recommendation) in pa-
tients after complex PCI [91]. Whereas the optimal dura-
tion of DAPT in patients after CTO PCI remains unknown, 
the tailored approach according to the clinical (diabetes, 
chronic kidney disease) and angiographic characteristics 
(e.g. number of stents, stent length, stent diameter) as 
well as the assessment of bleeding risk should be taken 
into account [13].
Complications and radiation issues
Despite the systematic decrease in CTO PCI-related 
complications, CTO PCI is associated with higher risk as 
compared with PCI of non-occluded coronaries [5]. Par-
ticularly, with the prevalence of 2.6–4.8% coronary per-
forations are the most common CTO PCI complications 
[92–94]. Significantly, most perforations occurring during 
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CTO PCI are benign, and can be treated conservatively. 
The rate of tamponade is significantly lower and ac-
counts for 0.4 to 1.3% of cases [2, 95]. Additional compli-
cations include: access site complications, donor vessel 
injury, arrhythmias, stroke, contrast-induced nephropa-
thy, radiation dermatitis, emergency bypass grafting and 
death [96]. The average complication risk in most regis-
tries ranges from 0.5% to 7.0%, but high between-study 
variability exists [94, 97]. For example, whereas the rate 
of death rate was 0% in the UK Hybrid registry (1 156 pa- 
tients), 0.2% and 0.9% death rates were reported in the 
EURO-CTO registry (17 626 patients) and OPEN-CTO reg-
istry (1 000 patients), respectively [94, 95, 98]. The po-
tential measures to minimize the risk of complications 
include: 1) dual catheter injection for mitigating the risk 
of dissection and/or perforation by determination of the 
guidewire position, 2) placement of safety wire in the 
CTO donor vessel, 3) maintaining an appropriate ACT lev-
el for preventing donor vessel thrombosis, 4) availability 
of covered stents and coils in case of perforation, 5) prop-
er hydration and limited contrast use (maximal amount 
of contrast defined as 4× of the pre-procedural eGFR) [4].
The reduction of the radiation dose encountered 
during CTO PCI should be the common goal of the whole 
CTO team. To this end, the ALARA protocol, with the aim 
of reducing radiation exposure to “As Low As Reasonably 
Achievable”, should be implemented in each catheteriza-
tion laboratory. Particularly germane to this concept, the 
basic rules to limit radiation exposure include: 1) use of 
low-frame rate fluoroscopy and fluoroscopy-store func-
tion for documenting balloon and stent inflation instead 
of cine-angiography, 2) use of collimation, 3) reduction 
of the distance between the image receptor and the pa-
tient, 4) keeping the maximal possible distance from the 
X-ray lamp, and 5) proper use of protective shields [4, 7].
CTO program and operators’ requirements
Training in such complex procedures as CTO should 
start after the full understanding and exposure to PCI in 
general. Nevertheless, sufficient training in regular PCI 
does not automatically translate into an ability to be-
come CTO operator. 
High procedural volume is required to achieve and 
maintain CTO PCI skills [55, 99]. According to the Euro 
CTO Club, a large-volume catheterization laboratory with 
more than 1,000 PCI cases/year can provide continuous 
training to no more than 1–2 operators in order to ex-
ceed the minimal number of 50 CTO PCI cases per year/
per operator. Since it is highly unlikely that the success 
rate will approach 80% in lower-volume centers, opera-
tors performing less than 30 CTO procedures annually 
should refer their patients to more experienced opera-
tors or involve proctors (particularly in CTO lesions with 
intermediate and high J-CTO scores) [5, 7]. It has been 
shown that while at least 100 CTO PCI/year must be per-
formed by an operator to achieve a success rate > 90%, 
the minimal number to achieve a success rate > 80% ap-
proximates 50 CTO PCI/year [2, 5]. Retrograde techniques 
should be reserved for experienced operators (prefera-
bly those performing > 50 CTO per year). A minimum of 
50 retrograde CTO PCI procedures (25 as a second oper-
ator and 25 as a first operator under supervision) might 
be advised before a  cardiologist becomes an indepen-
dent retrograde operator [7].
The minimal number of 50 CTO PCI per year to main-
tain competency translates into a  model where only 
a limited number of operators and centers should per-
form CTO revascularization. The basic set of techniques 
for developing expertise in CTO PCI is represented by 
antegrade wire escalation and should be followed by 
implementation of retrograde techniques and ADR. Em-
bracing the retrograde approach requires availability of 
specific devices (long microcatheters, dedicated wires, 
guide extensions, snares, etc.), learning several differ-
ent techniques (from collateral channel engagement to 
wire externalization) and readiness to deal with com-
plications (e.g. perforation, tamponade, donor vessel 
ischemia). Regarding collateral channel selection, it 
might be advisable to start tackling bypass grafts and 
septal channels first before embarking on retrograde 
CTO PCI via epicardial collaterals that represent the 
highest risk for life-threatening complications in case 
of rupture [5].
Hybrid algorithm according to the  
Association of Cardiovascular Interventions
We have provided a modified hybrid algorithm (Fig-
ure 2) combining the main features of the original hybrid 
algorithm by Brilakis et al. and the EuroCTO Club hybrid 
algorithm [5, 82]. Similar to both of these algorithms 
we differentiate 3 main characteristics that determine 
whether the primary approach is antegrade or retro-
grade: 1) proximal cap ambiguity; 2) quality of the distal 
vessel; and 3) interventional collaterals. Uniquely, we: 
1) specify the fundamental role of adjunctive coronary 
imaging (including IVUS and/or coronary CTA) as well as 
dedicated PCI techniques (balloon-assisted subintimal 
entry, scratch and go) to resolve proximal cap ambigui-
ty and consequently avoid or improve the efficiency of 
retrograde procedures; 2) justify the discretionary use of 
the Crossboss catheter for crossing in-stent CTO; 3) ac-
knowledge that both CTO length and ambiguous vessel 
course are equally important to dictate the choice of ei-
ther a wire escalation strategy or a dissection and re-en-
try strategy; 4) put emphasis on parallel wiring (including 
IVUS guided re-entry) as a reasonable option after failing 
antegrade wiring; and 5) define ADR as an equal alter-
native to antegrade wiring in CTO lesions with clear or 
resolved proximal cap, occlusion length ≥ 20 mm and no 
major bifurcation at the distal cap. In addition, the use of 
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ADR bail-out strategies (including antegrade fenestration 
and re-entry) has been underscored.
Reimbursement of CTO PCI
CTO PCI generally requires more procedural resourc-
es, and thus incurs higher procedural costs than regular 
PCI of non-CTO vessels. These costs are related to the 
use of multiple devices such as guiding catheters, guide-
wires, microcatheters (usually one or two depending on 
the use of retrograde approach), balloons, drug-eluting 
stents and closure devices, as well as specialized equip-
ment such as dissection and re-entry catheters (Cross-
Boss catheter and/or Stingray balloon), guide extension 
catheters and intravascular ultrasound catheters, and 
to a lesser frequency atherectomy devices, coils, hemo-
dynamic support devices or snares. This is particularly 
salient in percutaneous revascularization of CTO using 
the hybrid approach, wherein dual catheter injection 
and numerous modern CTO PCI techniques are applied 
ensuring high success rates exceeding 90%. Indeed, 
in a  recent cost analysis among 964 patients from the 
OPEN-CTO registry, the procedural costs of CTO PCI us-
ing the hybrid algorithm ($12,280 ±5,972) were compa-
rable to the costs of multivessel or left main PCI in the 
SYNTAX trial ($11,919 ±6,162) [100, 101]. Noteworthy, 
these costs did not account for other expenses such as 
nonprocedural hospital costs ($3,424 ±6,188) and physi-
cians’ fees ($1,344 ±427) that further increase the total 
cost of CTO PCI in the United States ($17,048 ±9,904) 
[100]. Noteworthy, the total cost of CTO PCI calculated 
for 10 randomly selected patients from the National 
Institute of Cardiology in Warsaw in 2019 averaged PLN 
15 505 ±6 169. Nevertheless, the cost of CTO PCI is still 
far lower than the cost of the alternate method of cor-
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Figure 2. Modified hybrid algorithm for CTO crossing according to the Association of Cardiovascular Interven-
tions of the Polish Cardiac Society
ADR – antegrade dissection and re-entry, AFR – antegrade fenestration and re-entry, AWE – antegrade wire escalation, BASE – balloon-assisted subinti-
mal entry, CART – controlled antegrade retrograde tracking, CT – computed tomography, CTO – chronic total occlusion, IVUS – intravascular ultrasound,  
RWE – retrograde wire escalation, STAR – subintimal tracking and re-entry.
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grafting (ranging between $44,824 to $448,038) in the 
United States [102]. 
Several countries have already provided higher reim-
bursement rates for CTO PCI than for regular PCI of non-
CTO lesions to account for the additional costs incurred 
during percutaneous recanalization of CTO. For example, in 
Germany the reimbursement rate for CTO PCI using either 
an antegrade or retrograde approach amounts to €4,500 
and exceeds the maximal reimbursement rate for non-CTO 
PCI (€3,500). Furthermore, in Japan and Singapore separate 
reimbursement for the devices used during the CTO PCI 
procedure (microcatheters, guidewires, balloons, stents, 
etc.) is secured. This is in contrast to the situation in Po-
land, where all CTO PCI are substantially underestimated 
and calculated as regular PCI. This, in turn, translates into 
excess expenditure for the still low number of healthcare 
providers offering CTO PCI, and further restrains guide-
line-recommended interventions among patients with CTO 
in Poland. The potential solution for this issue at a national 
level might rely on the institution of CTO PCI reference cen-
ters specialized in the most difficult CTO interventions (e.g. 
in lesions with J-CTO score ≥ 2).
Expert recommendations of the Association 
of Cardiovascular Interventions
1. Symptom improvement (including effort angina, dys-
pnea, and fatigue) is the primary indication for CTO PCI 
(based on randomized clinical trials). The secondary in-
dications for CTO PCI include improvement of clinical 
prognosis, increase in left ventricular systolic function 
and reduction of malignant arrhythmias (based on ob-
servational data and expert opinions only).
2. Referral for CTO PCI should be mainly based on clinical 
grounds (symptoms) as well as ischemia and/or viabil-
ity assessment. The clinical benefit of CTO PCI should 
be balanced against the procedural risk related to the 
specific clinical and angiographic characteristics.
3. Dual coronary angiography and meticulous analysis of 
the angiogram (and if available coronary CTA) are par-
amount for planning and safe recanalization of CTO.
4. The use of microcatheters is mandatory to enhance 
guidewire manipulation and ensure procedural safety.
5. There are 4 main strategies for CTO PCI: antegrade 
wire escalation, antegrade dissection and re-entry, 
retrograde wire escalation, and retrograde dissection 
and re-entry. The full-skilled CTO operator must not 
only be familiar with all of these techniques, but also 
quickly change from one technique to another in case 
of failure.
6. A hybrid algorithm has to be applied when planning 
and performing CTO recanalization.
7. Radiation and contrast safety issues must be metic-
ulously taken into account when planning and per-
forming CTO recanalization.
8. Dedicated CTO training and adequate procedural 
volume are essential to ensure high success and low 
complications rates. Operators embarking on the CTO 
PCI training program should start with easy and in-
termediate CTO lesions (J-CTO score of 0 and 1) and 
involve proctors in more difficult cases (J-CTO score 
≥ 2). Centers with a low number of CTO PCI (< 30 yearly) 
should refer difficult CTO cases to specialized CTO 
centers. The CTO operator must perform at least 
50 procedures annually to maintain skills and reduce 
the risk of complications.
9. The use of IVUS during CTO PCI is recommended for 
reduction of the risk of restenosis and re-occlusion 
and improvement of long-term clinical outcomes.
10. There is unmet need for an adequate number and 
high quality of CTO procedures in Poland, which are 
vastly underused due to significant financial con-
straints.
Summary
Coronary CTO are increasingly encountered during 
invasive and non-invasive coronary angiography. Note-
worthy, most patients with CTO have inducible ischemia 
and are symptomatic despite optimal medical therapy, 
rendering them ideal candidates for coronary revascular-
ization. Historically, based on its angiographic complex-
ity, the presence of CTO was the key driver for coronary 
artery bypass grafting or medical therapy only. During 
recent years, however, a  clear shift towards percutane-
ous treatment of CTO has been witnessed, particularly as 
a result of the unprecedented progress in CTO PCI tech-
niques and equipment as well as specialized training pro-
grams of CTO operators. In this regard, high success rates 
(exceeding 90% in some luminary centers) along with 
improved safety outcomes of CTO PCI can be achieved. 
Significantly, based on randomized clinical trials CTO PCI 
has been shown to relieve angina and enhance exercise 
tolerance, translating into improved quality of life. Nev-
ertheless, and contrary to the Western European coun-
tries, CTO PCI is significantly underused and accounts for 
less than 3% of all PCI in Poland, leaving many patients 
with CTO untreated and symptomatic. This mainly re-
sults from the barriers in obtaining the adequate skills, 
tools and training programs among Polish CTO operators 
as well as non-adequate financial support of CTO proce-
dures in Poland.
The current expert consensus document summariz-
es the rationale, clinical outcomes as well as technical 
and safety issues of CTO PCI. Significantly, we have pre-
sented a modified hybrid algorithm (the so-called Polish 
hybrid algorithm) providing some unique refinements 
to the contemporary CTO PCI strategies. Finally, a list of 
succinct and practical recommendations on CTO PCI has 
been provided. Continuous efforts of scientific societies 
and national associations (including active engagement 
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with the payer) are urgently needed to expand CTO PCI 
knowledge and training programs and close the gap be-
tween Poland and Western European countries.
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